医学
PD-L1
单克隆抗体
肿瘤科
抗体
单克隆
疾病
内科学
免疫学
免疫疗法
癌症
出处
期刊:Lancet Oncology
[Elsevier]
日期:2016-12-01
卷期号:17 (12): e527-e527
被引量:22
标识
DOI:10.1016/s1470-2045(16)30590-3
摘要
A new study by Stéphane Champiat (Gustave Roussy, Villejuif, France) and colleagues found that hyperprogressive disease was associated with older age (≥65 years) and worse overall survival in patients who had been treated with anti-PD-1/PD-L1 monoclonal antibodies.
科研通智能强力驱动
Strongly Powered by AbleSci AI